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Cell Biology/Signaling
Inhibition of Nitric Oxide–Stimulated Vasorelaxation by
Carbon Monoxide-Releasing Molecules
Antonia Marazioti, Mariarosaria Bucci, Ciro Coletta, Valentina Vellecco, Padmamalini Baskaran,
Csaba Szabó, Giuseppe Cirino, Ana Rita Marques, Bruno Guerreiro, Ana M.L. Gonc¸alves,
Joa˜o D. Seixas, Annie Beuve, Carlos C. Roma˜o, Andreas Papapetropoulos
Objective—Carbon monoxide (CO) is a weak soluble guanylyl cyclase stimulator, leading to transient increases in cGMP
and vasodilation. The aim of the present work was to measure the effect of CO-releasing molecules (CORMs) on the
cGMP/nitric oxide (NO) pathway and to evaluate how selected CORMs affect NO-induced vasorelaxation.
Methods and Results—Incubation of smooth muscle cells with some but not all of the CORMs caused a minor increase
in cGMP levels. Concentration-response curves were bell-shaped, with higher CORMs concentrations producing lower
increases in cGMP levels. Although exposure of cells to CORM-2 enhanced cGMP formation, we observed that the
compound inhibited NO-stimulated cGMP accumulation in cells and NO-stimulated soluble guanylyl cyclase activity
that could be reversed by superoxide anion scavengers. Reactive oxygen species generation from CORMs was
confirmed using luminol-induced chemiluminescence and electron spin resonance. Furthermore, we observed that NO
is scavenged by CORM-2. When used alone CORM-2 relaxed vessels through a cGMP-mediated pathway but
attenuated NO donor-stimulated vasorelaxation.
Conclusion—We conclude that the CORMs examined have context-dependent effects on vessel tone, as they can
directly dilate blood vessels, but also block NO-induced vasorelaxation. (Arterioscler Thromb Vasc Biol. 2011;
31:2570-2576.)
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Carbon monoxide (CO), which was previously consideredonly as a highly toxic and life-threatening pollutant, has
been recognized as a signaling molecule having regulatory
roles in many physiological and pathophysiological processes
within the cardiovascular, immune, and nervous systems.1,2
It is generated in mammalian tissues via the endogenous
degradation of heme by a family of constitutive (heme
oxygenase-2 and heme oxygenase-3) and inducible (heme
oxygenase-1) heme oxygenase enzymes.2 CO gas binds to
heme-containing proteins and exerts antiinflammatory and
antioxidant effects.2,3 In the cardiovascular system, CO ex-
hibits vasodilatory properties, prevents endothelial cell apo-
ptosis, controls vascular smooth muscle cell proliferation, and
inhibits platelet aggregation.3–5
It has been suggested that CO can be used as a therapeutic
agent; testing the beneficial actions of CO has been facilitated
by the discovery of molecules that release CO under appro-
priate conditions.1,6 Initial CO-releasing molecules (CORMs)
were transition metal carbonyls soluble only in organic
solvents and required the use of physical or strong chemical
stimuli to release CO.7,8 More recently, water-soluble
CORMs have been reported that liberate CO in a controlled
fashion in biological systems and have the potential to deliver
it to tissues and organs.9,10 Several uses have been proposed
for CORMs, ranging from inflammatory diseases and vascu-
lar dysfunction to tissue ischemia, organ rejection, and
sepsis.1 In the cardiovascular system, CORMs recapitulate
many of the effects of CO gas. CORMs induce vessel
relaxation in isolated aortic tissue and prevent coronary
vasoconstriction, as well as acute hypertension in vivo.11
Similar to nitric oxide (NO), CO can activate the hemo-
protein soluble guanylyl cyclase (sGC), but only weakly; CO
is reported to enhance sGC activity by 3- to 4-fold compared
with the maximal 200-fold activation triggered by NO.12 On
activation, sGC converts GTP to the second messenger
molecule cyclic guanosine monophosphate (cGMP), which
has an impact on many cellular functions.13 For example,
sGC is important in lowering smooth muscle tone and
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preventing platelet aggregation and leukocyte adhesion to the
vessel wall.13–15
In spite of the observations that CORMs reduce vessel
tone, the potential interactions between CORMs and vasodi-
lators that activate sGC (ie, NO donors) have not been
studied. To this end, we have synthesized several CORMs
and determined their ability to alter cGMP levels in cells
and to modulate NO-stimulated cGMP formation and
vasodilation.
Methods
Synthesis of ALFs and Detection of CO Release
The metal carbonyl CORMs (ALFXXX) were synthesized ac-
cording to published or modified procedures for the synthesis of
related complexes (see supplemental material, available online at
http://atvb.ahajournals.org). All compounds were characterized
by Fourier transform infrared spectroscopy, 1H nuclear magnetic
resonance, and C,H,N analysis. The compounds were prepared,
purified, and kept under N2 atmosphere in the dark. The solutions
of CORMs were freshly prepared before the experiments by
dissolving the compound in the appropriate solvent. The release
of CO from the metal carbonyl complexes (ALFXXX) under
normoxic conditions was assessed by a chromatographic method
(see supplemental material).
Cell Culture
Rat aortic smooth muscle cells (RASMCs) were isolated from 12- to
14-week-old male Wistar rats, 5 rats per isolation, as previously
described.16 More than 95% of cells isolated stained positive for
smooth muscle -actin. Cells between passages 2 and 5 were used
for all experiments. RASMCs were routinely cultured in Dulbecco’s
modified Eagle medium containing 4.5 g/L glucose and supple-
mented with 10% fetal bovine serum and antibiotics.
Determination of cGMP Levels in RASMCs
RASMCs were plated in 24-well plates. Cells were washed twice
with Hanks’ balanced salt solution and incubated in Hanks’ balanced
salt solution in the presence of 3-isobutyl-1-methylxanthine
(1 mmol/L) for 5 minutes. Cells were then treated with vehicle,
tempol (1 mmol/L), sodium nitroprusside (SNP) (10 ), diethyl-
amine NONOate (DEA/NO) (1 mol/L), a nonsaturated CO solution
(100 mol/L), or CORMs at various concentrations (1 to
300 mol/L) for 15 minutes. Media were then aspirated, and 200 L
of 0.1 N HCl was added into each well to extract cGMP. After 30
minutes, HCl extracts were collected and centrifuged at 600g for 10
minutes to remove debris. The supernatants were directly analyzed for
cGMP by enzyme immunoassay.
Determination of sGC Activity
Guanylyl cyclase activity was determined by formation of [-
32P]cGMP from [-32P]GTP. In short, reactions were performed for
10 minutes at 30°C in a final volume of 100 L, in a 50 mmol/L
HEPES, pH 8.0, reaction buffer containing 500 mol/L GTP,
1 mmol/L dithiothreitol, and 5 mmol/L MgCl2. Basal and DEA/NO
(1 mol/L)–stimulated guanylyl cyclase activity was measured in the
presence of CORMs (10 and 100 mol/L). To inhibit reactive
oxygen species (ROS) production superoxide dismutase (SOD) (100
IU/mL) was added in the mixture. Typically, 5 L of purified sGC
(10 ng/L) was used in each assay reaction.
Assessment of ROS Production by CORMs
Chemiluminescence was used to measure ROS production by freshly
prepared CORMs. L-012 (8-amino-5-chloro-7-phenylpyrido[3,4-
day]pyridazine-1,4-(2H,3H)dione sodium salt) is a very sensitive
chemiluminescence probe used to detect reactive oxygen and nitro-
gen species formation. Various CORMs (1 to 300 mol/L) were
added to 40 L of a PBS buffer containing 400 mol/L L-012.
L-012-enhanced chemiluminescence was immediately measured
with a chemiluminometer (Luminoskan, Labsystems, Melbourne,
Victoria, Australia) and reported as relative light units. In some
cases, 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy (tempol)
(1 mmol/L) was added to the mixture.
NO Quantification in Solution in the Presence
of CORM-2
The release of NO was measured using an amperometric NO-specific
probe (ISO-NOP) connected to the single channel free radical
analyzer (TBR 1025, World Precision Instruments). A 4-channel
recording system (Laboratory-Trax-4/16, World Precision Instru-
ments) was used to digitize the analog signal from the probe. The
ISO-NOP sensor was calibrated by mixing NaNO2 solution of
desired concentration with H2SO4 (0.1 mol/L) and NaI (0.1 mol/L).
The release of NO by DEA/NO in phosphate buffer, pH 7.4, was
then monitored continuously. Cumulative concentration responses
curves to DEA/NO were performed in the presence of vehicle or
CORM-2 (10 and 100 mol/L); the solution was constantly bubbled
with N2 to remove atmospheric oxygen.
Assessment of Hydroxyl Production by ALF186,
ALF409, and ALF436
The formation of oxygen-based radicals and ROS in solution from
the reaction between low-oxidation-state complexes and O2 was
tested in electron spin resonance experiments using 5-tert-
butoxycarbonyl 5-methyl-1-pyrroline N-oxide (BMPO) as a spin
trap.17 A stock solution of each CORM was prepared by dissolving
the compound in 1 mL of deoxygenated distilled water (MeOH was
used in the case of ALF436) under N2. Another stock solution of
BMPO was prepared with a concentration of 250 mmol/L. An
aliquot was taken from the CORM solution and 100 L from the
BMPO solution to a closed vial under N2, and deoxygenated distilled
water was added to make 1 mL total volume. The final concentration
of CORM was 200 mol/L, whereas the final concentration of
BMPO was 12.5 mmol/L for the ALF186 experiment and 25 mmol/L
for the others, ALF409 and ALF436. A sample was taken from this
solution, and a control spectrum was acquired before bubbling O2.
Oxygen was then bubbled in the solution for 3 to 4 minutes, and
another sample was taken and analyzed. The experiment was
performed in a quartz, planar, electron spin resonance cell, at room
temperature, microwave power of 2 mW, modulation frequency 100
kHz, modulation amplitude 0.1 mT.
Aortic Ring Preparation
Male Wistar rats (250 to 300 g; Harlan, Bresso, Italy) of 8 to 10
weeks of age were euthanized, and the thoracic aorta was rapidly
dissected and cleaned from fat and connective tissue. Rings were
denuded of the endothelium and placed in organ baths filled with
oxygenated (95% O2 to 5% CO2) Krebs solution at 37°C, mounted
to isometric force transducers, and connected to a Graphtec recorder.
Rings were initially stretched until a resting tension of 0.5 g was
reached and allowed to equilibrate for at least 30 minutes, during
which tension was adjusted. In each experiment aortic rings were
first challenged with phenylephrine (PE) (1 mol/L) until the
responses were reproducible. Aortic rings were contracted with PE
(1 mol/L). Once the plateau was reached, a cumulative
concentration-response curve to DEA/NO or S-nitroso-N-acetyl-L,L-
penicillamine (SNAP) (1 nmol/L to 10 mol/L) and CORM-2
(1 mol/L to 200 mol/L) in the presence or absence of 1H-
(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one (ODQ) (5 mol/L) were
performed. In another set of experiments, rings were pretreated with
200 mol/L CORM-2 for 15 minutes at resting tension, and then PE
was added to constrict the preparation. The increase in tension
induced by PE after CORM-2 preincubation was not significantly
different from control. DEA/NO or SNAP cumulative concentration-
response curves were then performed in the presence or absence of
SOD (100 IU/mL) or tempol (3 mmol/L).
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Statistical Analysis
Data are expressed as meansSE. Statistical comparisons between
groups were performed using 1- or 2-way ANOVA (data from cell
culture experiments were analyzed with 1-way ANOVA, whereas
data from vasorelaxation studies were analyzed by 2-way ANOVA)
followed by a post hoc test or Student t test as appropriate.
Differences were considered significant at P0.05. GraphPad Prism
software (version 4.02, GraphPad Software, San Diego, CA) was
used for all the statistical analysis.
Results
Detection of CO Liberated From CORMs
CO release form CORMs in cell-culture medium (Roswell
Park Memorial Institute medium/fetal bovine serum) is
summarized in the supplemental Table. Some CORMs
(ALF186, ALF409, ALF411, ALF432, and ALF436) lib-
erate 0.9 molar equivalents of CO after 2 hours. Inter-
estingly, when dissolved in PBS (pH 7.4), CO liberation
was enhanced in all cases, with the exception of ALF411.
This indicates that molecules present in the Roswell Park
Memorial Institute medium/fetal bovine serum medium
protect CORMs complexes from decomposition or quench
the CO formed. ALF411 behaves differently because it dis-
solves in Roswell Park Memorial Institute medium/fetal bovine
serum, but is completely insoluble in PBS. As expected, once in
solution its stability decreases and CO release occurs. The role of
O2 as the trigger for the liberation of CO from these complexes
is quite clear because under anaerobic conditions (N2), CO
release is blocked in all cases except that of ALF409, where a
small amount of CO is still liberated. In contrast to other
CORMs and in accordance to previous reports,1 the well-
known Ru(II) CORMs, CORM-2 [Ru(CO)3Cl2]2 and
CORM-3 [Ru(CO)3Cl(H2NCH2COO)] do not release any CO
in the headspace. On the contrary, they slowly release CO2
over 24 hours in solution.18
Effect of CORMs on cGMP Levels in
Cultured Cells
Exposure to a nonsaturated CO solution (100 mol/L) caused
a small, 50%, increase in cGMP levels in rat aortic smooth
muscle cells (Figure 1A). For comparison, under the same
conditions, stimulation of cells with the NO donor at
10 mol/L leads to a 30-fold increase in cGMP accumulation
(Figure 1B). Most CORMs when used at 1 and 10 mol/L
failed to increase cGMP levels in smooth muscle cells
(Supplemental Table ); among the compounds tested,
ALF436 increased cGMP by 3-fold at the lowest concentra-
tion used. For the more widely studied CORM-2 and
CORM-3, higher concentrations were also used. Cells treated
with CORM-2 showed a bell-shaped increase in cGMP
accumulation, whereas exposure to CORM-3 caused an
inhibition at the highest concentration used (300 mol/L)
(Figure 1C and 1D). The ability of CORM-2 to stimulate
cGMP levels was blocked by the sGC inhibitor ODQ or by
incubation of cells with hemoglobin (Supplemental Figure IA
and IB). Moreover, the inactive form of CORM-2 (lacking
the CO groups) did not alter cGMP accumulation (Supple-
mental Figure IC). The above data taken together suggest that
CORM-2 increased cGMP accumulation through CO-
dependent activation of sGC.
Effect of CORMs on Recombinant sGC Activity
We next evaluated whether CORMs exert a direct effect on
sGC activity by using recombinant rat sGC. In contrast to the
increase in cGMP accumulation observed with cultured cells,
no increase in sGC activity was observed after incubation
with CORM-3 and CORM-2 at the concentrations used
(Figure 2A). On the other hand, the NO-stimulated sGC
activity was markedly reduced in a concentration-dependent
manner by these CORMs (Figure 2B).
Generation of ROS and Scavenging of NO
by CORMs
To study the mechanism through which CORMs reduce
NO-stimulated cGMP formation, we initially measured the
ability of CORMs to generate ROS. ROS production from
CORM-2 was concentration dependent, plateauing at a
100 mol/L concentration of this CORM, and could be
abolished by addition of tempol, an O2 scavenger (Figure 3A
and 3B). Two other molybdenum-based CORMs, ALF186
and ALF436, also increased ROS production (Supplemental
A
C D
B
Figure 1. cGMP levels in rat aortic smooth muscle cells
(RASMCs) treated with NO and CO donors. Confluent RASMCs
were treated with vehicle, 100 mol/L CO (A), 10 mol/L
sodium nitroprusside (SNP) (B), or the indicated concentrations
of CO-releasing molecule (CORM)-3 (C) or CORM-2 (D) in the
presence of 3-isobutyl-1-methylxanthine for 15 minutes. cGMP
was extracted and measured as described in the Methods sec-
tion. Data are expressed as percentage of the respective vehi-
cle, which was set as 100%; n4 to 12; *P0.05 compared
with vehicle.
A B
Figure 2. Effect of selected CORMs on purified soluble guanylyl
cyclase (sGC) enzyme activity. The activity of recombinant sGC
was measured following addition of 10 or 100 mol/L of the
indicated CO-releasing molecules (CORMs) in the absence (A)
or presence (B) of diethylamine NONOate (1 mol/L); n3;
*P0.05 compared with vehicle.
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Figure IIA and IIB). The ALF186- and ALF436-induced
ROS released was inhibited by tempol (Supplemental Figures
IIIB and IVB). In a separate series of experiments, we
observed that the electron spin resonance spectra obtained for
the solutions of ALF186 (or CORM-3, ALF409, ALF436;
data not shown) after bubbling O2 revealed a very strong and
clean signal assignable to the hydroxyl adduct of BMPO
(Figure 3C). Thus, although CO from CORMs activates sGC
in an NO-independent and, thus, superoxide-insensitive man-
ner, the ROS generated by CORMs would be expected to
inhibit NO-stimulated guanylyl cyclase activity.
To assess whether CORM-2 can react with NO, we
measured NO using an NO electrode (Figure 3D). In these
experiments, we observed that CORM-2 attenuated the
amount of NO in solution released by DEA/NO in a
concentration-dependent manner. When NO levels were mea-
sured in a 10 mol/L DEA/NO solution, they were found to
be decreased by 80% when a 10-fold excess of CORM-2 was
present. Similar observations were made using SNP as a
donor (data not shown). Using a different experimental setup,
we confirmed that CORM-2 quenched NO; scavenging of
NO by CORM-2 was favored when CORM-2 is present in
excess (10-fold) relative to NO (Supplemental Figure V).
Interaction of CORMs With NO Donors in Cells
To study whether CORM-2 reduces NO donor-stimulated
cGMP accumulation in cells, RASMCs were exposed to SNP
or DEA/NO, and cGMP was measured. Indeed, CORM-2
attenuated cGMP formation in response to both NO donors,
confirming and extending in a cellular milieu the in vitro
biochemical findings that CORMs release ROS and attenuate
cGMP formation. Interestingly, responses to SNP (Figure
4A) were affected more than those to DEA/NO (Figure 4B).
In cells treated with tempol, the ability of CORM-2 to reduce
DEA/NO-induced cGMP accumulation was attenuated (Sup-
plemental Figure VI). The 2 molybdenum-based CORMs,
ALF186 and ALF436, also reduced NO-stimulated cGMP
accumulation in cultured cells (Supplemental Figure IIC and
IID) in a tempol-reversible manner (Supplemental Figures
IIIA and IVA).
Additional evidence for the role of ROS in CORMs-
mediated inhibition of NO-induced cGMP formation was
obtained in sGC activity assays. High concentrations of CO
(700 mol/L) decreased NO-stimulated sGC activity by
20% (data not shown); cGMP formation was even more
reduced after exposure to CORM-2; when SOD was added to
the sGC activity assay mixture to remove any O2 formed, the
effect of CORM-2 was partially reversed (Figure 4C).
Effect of CORM-2 on Vascular Tone
CORM-2 administration caused a concentration-dependent
relaxation that reached approximately 60% relaxation at the
highest concentration used (Figure 5A). CORM-2-induced
relaxation was abolished by ODQ, suggesting that the relax-
ation is mediated by sGC. Exposure to the NO donor
DEA/NO led to a full relaxation that was observed at a much
lower concentration than the one needed for maximal
Figure 3. CO-releasing molecules (CORMs) release reactive
oxygen species. Superoxide anion release by the indicated con-
centration of CORM-2 was measured by chemiluminescence
(A). The superoxide anion scavenger tempol (1 mmol/L) was
used to quench O2
 produced from CORM-2 (100 mol/L) (B).
Electron spin resonance spectrum obtained after bubbling O2 in
a water solution containing 5-tert-butoxycarbonyl 5-methyl-1-
pyrroline N-oxide (BMPO) and ALF186 (C). NO concentration in
a solution containing 1 to 10 mol/L diethylamine NONOate
(DEA/NO) in the presence of different CORM-2 concentrations
(10 to 100 mol/L) (D); n3; *P0.05 compared with vehicle. P 
0.05 compared with CORM-2. RLU indicates relative light units.
A B
C
*
#
*
* #
* #
*
Figure 4. CO-releasing molecule (CORM)-2 reduces
NO-induced cGMP formation. Rat aortic smooth muscle cells
were treated with vehicle, sodium nitroprusside (SNP) alone
(0.1 mol/L, A), diethylamine NONOate (DEA/NO) alone
(1 mol/L, B) or a combination of the NO donor with CORM-2
(200 mol/L) in the presence of 3-isobutyl-1-methylxanthine for
15 minutes. cGMP was extracted and measured as described in
Methods section. The activity of the NO-stimulated purified sol-
uble guanylyl cyclase (sGC) was measured after addition of
CORM-2 (10 mol/L) in the presence of the endogenous super-
oxide dismutase (SOD) (100 IU/mL) (C). Data are expressed as
percentage of the respective vehicle, that was set as 100%;
n3 to 8; *P0.05 compared with vehicle, #P0.05 compared
with CORM-2. #P0.05 compared with SNP, DEA/NO, or
CORM-2.
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CORM-2 relaxation (Figure 5B). To assess whether CORM-2
could interfere with the vasodilation triggered by exoge-
nously administered NO, relaxation curves to DEA/NO were
repeated in the presence of a maximally dilating CORM-2
concentration. It should be noted that the contractile response
to PE was not significantly affected by the preincubation with
CORM-2. This might be due to the fact that the CORM-2-
induced vasodilation is short-lived and is no longer observed
after the preincubation, or due to the fact that the vasorelaxing
action of CORM-2 is only displayed when this agent is
applied to a tissue after, but not before, it develops an
elevated tone. In line with what we observed in the experi-
ments with purified sGC and cultured cells, NO-induced
relaxation was attenuated by CORM-2. The inhibitory effect
of CORM-2 in NO-induced vasodilation was reduced by
SOD (Figure 5C) and tempol (Figure 5D). Similar results
were obtained using a different NO donor SNAP. In a manner
analogous to that observed with SNP responses in cultured
cells, the vasorelaxing action of SNP was inhibited to a
greater extent by CORM-2 (Supplemental Figure VII).
Discussion
The derivatives of the fragment fac-[RuII(CO)3)], CORM-2,
and CORM-3 are the most commonly reported examples of
metal carbonyl complexes used as vehicles to deliver CO to
cells and tissues.1 The CO releasing capacity of these com-
pounds has been measured by their ability to rapidly (1
minute) transfer 1 CO to deoxy-Mb, forming carbonmonoxy-
myoglobin. However, we and others1,19 have observed that
these compounds do not release CO as a free gas. Thus, CO
from CORM-2 and CORM-3 is assumed to be first trans-
ferred to a biological molecule forming an intermediate that
delivers CO in living systems.1 In the present study, we
introduced a different group of CORMs based on zero-valent
molybdenum carbonyls. In contrast to the previous Ru(II)
complexes, these Mo(0) compounds are able to release CO as
a free gas to their biological environment once they are
activated by molecular oxygen.
All but one of the molybdenum-based CORMs, in spite of
releasing measurable amounts of CO in cell culture media,
failed to stimulate cGMP production in cultured vascular
smooth muscle cells. The one that did (ALF436) increased
cGMP only marginally, and this effect was lost when higher
concentrations were used. From our in vitro studies, it
became apparent that cGMP accumulation in cultured smooth
muscle cells is not a good bioassay to test for biological
activity of molybdenum-based CORMs. Among the
ruthenium-based CORMs (CORM-2 and CORM-3), neither
of which release CO to the headspace but rather transfer CO
to heme-containing biological molecules, only CORM-2
increased cGMP accumulation. However, CORM-3 has been
reported to promote vasodilation in an ODQ-inhibitable
manner and to increase cGMP levels in vascular tissue.9 The
cGMP-elevating effect of CORM-3 was shown to be dimin-
ished by endothelium removal or endothelial nitric oxide
synthase inhibition, suggesting that CORM-3 might be act-
ing, at least in part, by enhancing endogenous NO release
rather than through a direct effect on sGC.9 Of note, cGMP-
independent mechanisms of CORM-induced smooth muscle
relaxation have also been shown to exist. These are mediated
through big conductance calcium-activated potassium chan-
nels: the opening of these channels leads to membrane
hyperpolarization, which in turn closes voltage-dependent
calcium channels, reduces calcium levels, and relaxes smooth
muscle.20
To examine whether CORMs directly activate sGC, we
tested the 2 most studied CORMs to date (CORM-2 and
CORM-3) for their ability to stimulate recombinant sGC. In
line with previous observations, CORM-3 did not enhance
sGC activity in vitro9; neither did CORM-2. CORM-3 has
been shown to increase sGC activity in the presence of the
sGC sensitizer YC-1.9 The fact that CORM-2 increased
cGMP formation in cells but not in the sGC activity assay
could be explained by the existence of an endogenous
YC-1-like sGC sensitizer21 in smooth muscle cells. Alterna-
tively, the formation of an intermediate/metabolite might be
required for the transfer of CO from these CORMs to sGC
and this only occurs in cells. Surprisingly, we found that both
CORMs markedly and dose-dependently inhibited NO stim-
ulated sGC activity. This inhibitory action of CORM-2 and
CORM-3 on NO-stimulated sGC has not been reported
before and could be explained by (1) a partial agonist effect
of CO on sGC activation, (2) ROS generation by the CORMs
that inactivates NO, or (3) quenching of NO by the transition
metal complexes. Experiments were therefore designed to test
the above-mentioned hypotheses.
CO binds to the sGC heme with considerably lower affinity
and is a much weaker sGC stimulator compared with NO.22,23
C D
BA
Figure 5. CO-releasing molecule (CORM)-2 causes vasodilation,
but inhibits NO-stimulated relaxation. Rat aortic rings were pre-
contracted with phenylephrine, and relaxation was triggered
with increasing concentrations of CORM-2 (1 to 200 mol/L) in
the presence or absence of 5 mol/L 1H-(1,2,4)oxadiazole(4,3-
a)quinoxalin-1-one (ODQ) (A). Rings were pretreated with
CORM-2 (200 mol/L) or vehicle for 15 minutes and then con-
tracted with phenylephrine; they were then exposed to increas-
ing concentrations of the NO donor diethylamine NONOate
(DEA/NO) (B). Phenylephrine-contracted rings were incubated
with SOD (100 IU/mL, C) or tempol (3 mmol/L, D) for 15 minutes
before being exposed to CORM-2 (200 mol/L); DEA/NO was
then added at the indicated concentration to elicit vasorelax-
ation. Data are meanSEM; n4; *P0.01 compared with vehi-
cle, #P0.05 compared with CORM-2.
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tion of NO-stimulated sGC activity, suggesting that CO, can
act as partial agonist if present in great excess. Because of the
different affinity for sGC exhibited by NO and CO, the
antagonistic action of CO would only be observed if phar-
macological amounts of CO are delivered and would be of no
importance under physiological conditions. Incubation of
recombinant sGC with CORM-2 caused an even greater
decrease in NO-stimulated sGC activity than that caused by
the CO-saturated solution. The decrease in sGC activity was
partially restored by SOD, suggesting that the inhibition of
sGC activity by CORM-2 involves at least 2 mechanisms
(partial agonism and ROS generation). To provide experi-
mental evidence that CORM-2 generates ROS, we measured
the production of ROS from CORM-2 using a chemilumines-
cent dye. In these experiments, we could demonstrate a
concentration-dependent increase in chemiluminescence that
was blocked by incubation with tempol, indicating that
superoxide anions are generated from CORM-2. In addition,
scavenging of superoxide anions limited the ability of
CORM-2 to inhibit DEA/NO-stimulated cGMP formation in
cells. ROS generation was also noted with the molybdenum
complexes (ALF186 and ALF436). In addition, the inhibition
of NO-induced cGMP formation by ALF186 and ALF436
could be rescued by tempol. It thus seems that Mo-based
CORMs are not devoid of the drawbacks seen with the
Ru-based compounds.
CORM-3, ALF186, ALF409, and ALF436 released hy-
droxyl radicals after exposure to O2. For the Mo(0) CORMs,
it is quite plausible that hydroxyl radicals originate from the
metal catalyzed decomposition of O2 initially formed, but we
have not investigated this issue further. It is worth noting that
in spite of the known antioxidant properties of CO, CORM-3
has also been shown to increase O2 production and constrict
renal arteries in a dose-dependent manner.24 The effect of
CORM-3 in renal arteries was, however, proposed to involve
the activity of multiple oxidases including nitric oxide syn-
thase, NADPH oxidase, xanthine oxidase, and complex IV of
the mitochondrial electron chain. Thus, CORM-3 might
generate ROS both directly and indirectly in biological
systems. As sGC activity is known to depend on the existence
of reduced thiol groups,13,25 it is tempting to speculate that
cGMP accumulation in cells is biphasic, showing reduction at
higher CORM concentrations (see Figure 1) due to the
generation of ROS from CORMs and oxidation of critical
sGC cysteine residues. If ROS production from CORM is
excessive, it would be possible to observe an inhibition of
sGC activity that masks any activation of sGC by the CO
delivered.
It has been previously reported that ruthenium complexes
have a high affinity for NO and effectively scavenge NO in
biological systems.26,27 In fact, efforts to design drugs that
scavenge NO and prevent some of its deleterious effects
include the synthesis of structures based on Ru complexes.28
To test whether CORM-2 quenches NO, we used 2 different
approaches. Both in the NO electrode experiments and in the
measurements of NO remaining in solution after incubation
with CORM-2, we observed that CORM-2 scavenged NO
and removed it from the solution in a time and concentration-
dependent manner. Thus, when ruthenium-based CORMs are
used as pharmacological tools, they would be expected to
lower NO concentrations in tissues.
It has been previously reported that CORM-2 relaxes
precontracted vessels.11 In agreement with these observa-
tions, we observed a vasorelaxing effect of this CORM that
was first evident at 100 mol/L and reached an 60%
decrease in vessel tone at 200 mol/L. In addition, inhibition
of sGC abolished the effects of CORM-2, indicating that sGC
activation and cGMP elevation mediate the vasodilatory
effect of CORM-2 in this preparation. However, in a manner
analogous to that seen with recombinant sGC and cells, we
also observed that CORM-2 attenuated NO donor–induced
vasorelaxation. The magnitude of the inhibitory responses of
CORM-2 toward NO-driven dilation varied with the donor
used; responses to SNAP were affected more than those to
DEA/NO. In agreement with what we observed with purified
sGC and cultured cells we saw that scavenging O2 reduced
the defect in relaxation caused by CORM-2. However, the
effect of both SOD and tempol in preventing the effects of
CORM-2 on NO-stimulated dilation was weaker compared
with that observed with the purified enzyme or cells. Given
that tissues have a higher antioxidant capacity, the inhibitory
action of CORM-2 in aortic ring relaxations might be mainly
due to scavenging of the NO released by CORM-2; the
CORM-2:DEA/NO ratio was, for most of the concentration-
response curves in the relaxation experiments, much
higher than the CORM-2:NO donor ratio in the activity
experiments; thus, even if ROS are removed by antioxi-
dants, NO would still be scavenged in the organ bath
experiments by CORM-2.
In summary, we have shown that CORMs do not activate
purified sGC, but are capable of elevating cGMP levels in
cells and causing sGC-mediated vasorelaxation. More impor-
tantly, we have shown that currently available CORMs based
on transition metal carbonyl scaffolds inhibit NO-induced
signaling and vasorelaxation through multiple mechanisms
that include ROS generation and direct scavenging of NO.
The final biological effect of any CORM would depend
on the amount of CO released by the CORM, the levels of
endogenously produced NO, the concentration of CORM
present that might react with NO, the amount and species of
ROS produced as a byproduct of CORM breakdown, and the
levels of antioxidants enzymes and chemicals present in the
tissues. Design of improved, “second-generation” CORMs
devoid of unwanted properties (ROS generation, NO scav-
enging) is needed for this class of compounds to be used in
establishing the therapeutic utility of CO in preclinical and
clinical models.
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SUPPLEMENT MATERIAL 
Materials and Methods 
Materials 
DMEM, HBSS, and FBS were obtained from GIBCO-BRL (Paisley, UK). Cell 
culture flasks and plates were obtained from Greiner Labortechnik (Frickenhausen, 
Germany). Dulbecco’s PBS, penicillin, and streptomycin were from Biochrom 
(Berlin, Germany). cGMP enzyme immunoassay kits were purchased from Assay 
Designs (Ann Arbor, MI). Tempol, L-NAME, ODQ, IBMX, S-nitroso-N-
acetylpenicillamine (SNAP), 1,1-diethyl-2-hydroxy-2-nitroso-hydrazine (DEA/NO), 
superoxide dismutase (SOD), sodium nitroprusside (SNP), CORM-2 and all other 
chemical reagents were purchased from Sigma (St. Louis, MO). L-012 (8-amino-5-
chloro-7-phenylpyrido[3,4-d]pyridazine-1,4-(2H,3H)dione sodium salt) was 
purchased from Wako Pure Chemical Industries (Osaka, Japan). The spin trap NWT-
BMPO, >99% was purchased from Northwest Life Sciences Specialties, LLC 
(Vancouver, WA). 
 
Synthesis of ALFs and detection of CO release 
The metal carbonyl CO-RMs ALF1861, ALF4112, CORM-33 were synthesized 
according to published procedures: ALF436 was adapted from van Staveren et al4;   
ALF409 was prepared by a modification of the method reported for the analogue 
[Et4N]+ salt5 and ALF432 was prepared in a similar way as described below.  
 
Preparation of tricarbonyl(N-(p-carboxy-benzyl)bis(2-picolyl)amine)Mo(0) (ALF436) 
The N-(p-carboxy-benzyl)bis(2-picolyl)amine ligand was prepared as follows: 
To a clear THF solution of methyl-4-(bromomethyl)benzoate (1.13 g, 4.85 mmol; 
229.08 g/mol) was added at once the yellow di-2(-picolyl)amine (0.903 ml; 4.85 
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mmol; 1.107 g/ml; 199.25 g/mol) at room temperature. The solution turns light 
yellow. Triethylamine (675 μL; 4.85 mmol; 0.727 g/ml; 101.19 g/mol) is added and 
the solution turns immediately deep yellow. The mixture was allowed to reach room 
temperature and subsequently filtered to remove a white precipitate. After removal of 
the solvent under reduced pressure, the orange oily residue was dissolved in diethyl 
ether (40 ml) and filtered to remove some more precipitate. Evaporation of the solvent 
gives a dark orange oil which was used in the next step.  
1H NMR (CDCl3, 400 MHz, rt; δ in ppm): δ = 8.49 (d,2H), 7.98 (d,2H), 7.64 (dt,2H), 
7.53 (d,2H), 7.48 (d,2H), 7.12 (tt,2H), 3.89 (s,3H), 3.81 (s,4H), 3.75 (s,2H). Note: 
There is a 5% of the di-2(-picolyl)amine used in slight excess; 
 
The orange oil was dissolved in methanol (20 ml) and a solution of aqueous NaOH 
(0.8 g in 5 ml H2O; 20 mmol; 40 g/mol) was added. The solution gets immediately 
darker and is stirred for two hours at room temperature. The pH was adjusted to 7 by 
dropwise addition of 2M HCl (50 ml HCl 37% in 250 ml water solution) followed by 
removal of the solvent under reduced pressure. The sticky yellow residue was ground 
with CHCl3 (200 ml) followed by filtration to remove NaCl. Removal of the solvent 
under reduced pressure afforded an orange sticky oil to which acetonitrile (30 ml) was 
added, followed by vigorous stirring to dissolve all compound. Precipitation is seen 
after 15 minutes. The solution was placed in the refrigerator to effect further 
precipitation. The white precipitate was filtered and dried under vacuum. Yield: < 
20%. 
 E.A. Calc. for N3O2C20H19: %C:72.05, %H:5.74, %N:12.60; Found: %C:72.57, 
%H:5.98, %N:13.04; 
1H NMR (CDCl3, 400 MHz, rt, δ in ppm): δ = 8.61 (d,2H), 8.01 (d,2H), 7.70 (dt, 2H), 
7.60 (d,2H), 7.44 (d,2H), 7.12 (t,2H), 3.88 (s,4H), 3.77 (s,2H). 
 
Synthesis of the complex ALF436: 
Mo(CO)3(η6-C7H8) (0.800 g; 2.94 mmol; 272.1117 g/mol) was dissolved in 40 ml of 
MeOH and added to (C5H4CH2)2NCH2C6H4COOH (0.980g; 2.94 mmol; 333.39 
g/mol) in 25 ml of MeOH. 
The red clear solution became turbid with an abundant insoluble precipitate after 
5minutes. The reaction was carried on for 2h at room temperature. The precipitate 
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was allowed to rest and was filtered. It was washed with 25 ml of Et2O and dried in 
vacuum giving a bright orange powder. Yield: 86%. 
IR (KBr/cm-1; C≡O): 1899(vs), 1759(s); 
E.A. Calc. for C23H19N3MoO5: %C=53.81, %H=3.73, %N=8.19; Found: %C=54.01, 
%H=3.79, %N=7.79; 
1H NMR ((CD3)2CO, 400MHz, rt, δ in ppm): δ = 8.85 (d,2H); 8.14 (d,2H), 7.88 
(d,2H), 7.61 (d,2H), 7.21 (d,2H), 7.11 (d,2H), 4.80 (s,2H), 4.73 (d,2H), 3.92 (d,2H). 
 
Preparation of Na3[Mo(CO)3(citrate)] (ALF409) 
The general procedure is presented for Na3[Mo(CO)3(citrate)]: 
Sodium citrate dihydrate (0.844 g; 2.801 mmol; 294.1 g/mol) and (η6-C7H8)Mo(CO)3 
(0.780 g; 2.866 mmol; 272.12 g/mol) were suspended in 100 ml of dry MeOH and 
stirred for 24 hours at room temperature. The light orange solution was filtered and 
concentrated under vacuum. This was transferred to another schlenk, partially filled 
with a large amount of Et2O. A flocculate precipitate was obtained and filtered. It was 
washed with Et2O and dried in vacuum to afford a light brown powder. Yield: 74%.  
IR (KBr/cm-1): 1984(w), 1901(s) (C≡O); 1754(br), 1599(br); 1410(m) (C=O); 
E.A. Calc. for MoC9H5O10Na3.2(CH3OH): %C:26.31, %H:2.61; Found: %C:26.49, 
%H:2.21; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 2.67 (s,1H); 2.63 (s,2H), 2.57 (s,1H), 2.53 
(s,1H).  
 
Preparation of Na5[Mo(CO)3(diethylenetriaminepentaacetate)]  (ALF432) 
The compound was prepared as ALF409 above. 
Yield: 80%; 
IR (KBr/cm-1):1897(s) (C≡O); 1753(br), 1600(br), 1401(m) (C=O); 
E.A. Calc. for MoC17H18O13N3Na5.(CH3OH): %C=30.23, %H=3.10, %N=5.87;  
Found: %C=29.83, %H=3.66, %N=5.66; 
1H NMR (D2O, 400MHz, rt, δ in ppm): δ = 2.8-3.9 (broad band). 
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The solutions of CO-RMs were freshly prepared before the experiments by dissolving 
the compound in the appropriate solvent. The release of CO from the metal carbonyl 
complexes (ALFXXX) under normoxic conditions was assessed by a 
chromatographic method. Typically, 10-30mg of each compound were incubated with 
3ml of RPMI/FBS containing 10% Fetal Bovine Serum, with magnetic stirring in a 
closed vessel at 370C, in the dark. The atmosphere of this vessel was CO2 free, 
reconstituted air. Samples of the homogenized headspace were taken at 2hr and the 
amount of CO gas quantified by GC with TCD detection. Depending on the 
compound, the total amount of gas liberated in these experiments was in the order of 
1-3 ml (Table I).  
 
NO Detection 
In the present study we assessed the effect of CORM-2 in the NO release by DEA/NO 
using an amperometric NO-specific probe (ISO-NOP) connected to the single channel 
free radical analyzer (TBR 1025, World Precision Instruments). A four channel 
recording system (Lab-Trax-4/16, World Precision Instruments) was used to digitize 
the analog signal from the probe. The ISO-NOP sensor was calibrated immediately 
before the experiment following the manufacturing specifications. Briefly, the 
calibration procedure involves two solutions (0.1M H2SO4 + 0.1 M KI, and 50μM 
NaNO2) and it is based on the following reaction  
2NaNO2 + 2KI +2H2SO4 ? 2NO +I2+ 2H2O +2K2SO4 
The ISO-NOP sensor was immersed in 5ml of the solution containing iodide and a 
positive potential of 860 mV (Ag/AgCl reference electrode) was applied. Increasing 
amount of NaNO2 (12.5, 25, 50, 100, and 200 µl) were added to produce a known 
amount of NO. The concentration of NO generated can be calculated directly from the 
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stoichiometry since KI and H2SO4 are present in great excess and the reaction goes to 
completion. NO diffuses across the gas permeable (NO-selective) membrane and is 
oxidized at the working electrode surface producing a redox current which is 
measured. Once the calibration procedure ended the probe was immersed in 5ml of 
phosphate buffer at pH 7.4 and the release of NO by the NO donor DEA/NO was 
monitored continuously. Cumulative concentration response curves to DEA/NO were 
performed by adding increasing DEA/NO concentrations in presence or absence of 
CORM-2 (10 and 100 µmol/L) under constant nitrogen bubbling. A higher DEA/NO 
concentration was added once a plateau was reached (typically within 2-3min). 
Vehicle (DMSO) or CORM-2 were added immediately before the first addition of 
DEA/NO.  
 
NO quantification in solution in the presence of CO-RM 
NO in solution was determined by measuring nitrite (NO2-) concentration using the 
Griess reagent. As NO reacts with oxygen producing NO2- in equimolar 
concentrations, the reaction between NO and CORM-2 was performed in the absence 
of air, in deoxygenated vials using deoxygenated water. At each time point an aliquot 
of the reaction mixture was removed from the vials. A NO saturated solution (2 mM) 
was mixed with different concentrations of CORM-2 [solubilized in 10% dimethyl 
sulfoxide (DMSO)] in order to have the following ratios of CORM-2 to NO:  1:1 (0.5 
mM CORM-2: 0.5 mM NO); 10:1 (5 mM CORM-2: 0.5 mM NO) and 20:1 (10 mM 
CORM-2: 0.5 mM NO). After 5-60min a sample of each reaction mixture was 
removed from the vial and allowed to stand in room air; some samples were incubated 
with nitrate reductase (0.0025U/ml nitrate reductase) for 30 min at 30ºC to convert 
nitrate to nitrite.  After the addition of the Griess reagent, the mixtures were left at 
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room temperature for 10 minutes and then the absorbance of the solutions was 
measured at 550 nm in a microplate reader. Standard curves were constructed using 
NaNO2. 
 
Assessment of hydroxyl production by ALF186, ALF409 and ALF436 
The formation of oxygen based radicals and ROS species in solution from the reaction 
between low oxidation state complexes and O2, was tested in ESR experiments using 
BMPO as a spin trap 6.  A stock solution of each CO-RM was prepared by dissolving 
the compound in 1 mL of deoxygenated distilled water (MeOH was used in the case 
of ALF436) under N2. Another stock solution of BMPO was prepared with a 
concentration of 250 mM. An aliquot was taken from the CO-RM solution and 100 
μL from the BMPO solution to a closed vial under N2 and deoxygenated distilled 
water added to perform 1 ml total volume. The final concentrations of CO-RM were 
200µM whereas the final concentration of BMPO was 12.5 mM for the ALF186 
experiment and 25mM for the other ALF409 and ALF436. A sample was taken from 
this solution and a control spectrum was acquired before bubbling O2. Oxygen was 
then bubbled in the solution for 3-4 min and another sample was taken and analyzed. 
The experiment was performed in a quartz, planar, ESR cell, at room temperature, 
microwave power of 2 mW, modulation frequency 100 kHz, modulation amplitude 
0,1 mT. 
 
Aortic ring preparation 
Male Wistar rats (250–300 g; Harlan, Bresso, Italy) of 8–10 wk of age were killed, 
and the thoracic aorta was rapidly dissected and cleaned from fat and connective 
tissue. Rings of 2–3mm length were cut, denuded of the endothelium and placed in 
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organ baths (2–5 ml) filled with oxygenated (95% O2-5% CO2) Krebs solution at 
37°C and mounted to isometric force transducers (type 7006, Ugo Basile, Comerio, 
Italy) and connected to a Graphtec recorder (WR 3310). The composition of the Krebs 
solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgCl2 0.0012, KH2PO4 
0.0012, CaCl2 0.0025, NaHCO3 0.025, and glucose 0.010. Rings were initially 
stretched until a resting tension of 0.5 g was reached and allowed to equilibrate for at 
least 30 min during which tension was adjusted, when necessary, to a 0.5 g, and 
bathing solution was periodically changed. In a preliminary study, a resting tension of 
0.5 g was found to develop the optimal tension to stimulation with contracting agents. 
In each experiment aortic rings were first challenged with PE (1μΜ) until the 
responses were reproducible. Aortic rings were contracted with PE (1μΜ). Once the 
plateau was reached, a cumulative concentration-response curve to DEA/NO or 
SNAP with or without CORM-2 was performed; in some experiments rings were 
exposed to increasing concentrations of CORM-2 (1μΜ-1mM) in the presence of 
ODQ (5μΜ). In another set of experiments, rings were incubated with 200μΜ 
CORM-2 and SNAP cumulative concentration-response curve was performed in the 
presence or absence of SOD (300IU/ml) or tempol (3mM).   
 
Determination of soluble guanylyl cyclase activity 
GC activity was determined by formation of [α-32P]cGMP from [α-32P]GTP as 
previously described using semi-purified rat sGC7. In short,  reactions were performed 
for 10 min at 30°C in a final volume of 100 μl, in a 50 mM HEPES, pH 8.0, reaction 
buffer containing 500 μM GTP, 1 mM DTT, and 5 mM MgCl2. Basal and DEA-
NO(1μΜ)-stimulated guanylyl cyclase activity was measured in the presence of CO-
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RMs (10 and 100μΜ). To inhibit ROS production SOD (100IU/ml) was added in the 
mixture. Typically, 5 μl of purified sGC (10 ng/μl) was used in each assay reaction.  
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Figure Legends 
Figure I. CORM-2 stimulates cGMP by releasing CO and activating sGC in cells. 
Confluent RASMCs were treated with vehicle, CORM-2 10μΜ in the presence or 
absence of hemoglobin (1μM; A), or ODQ (10μΜ, 30min pre-treatment; B) in the 
presence of IBMX for 15min. In (C), cells were treated with the inactive CORM-2 
(RuCl3, 20μM) in the presence or absence of DEA/NO (1μΜ). cGMP was extracted 
and measured as described in Methods section. Data are expressed as percentage of 
respective vehicle which was set as 100%; n=4-8; *P<0.05 from vehicle, #P<0.05 
from CORM-2 or DEA/NO. 
 
Figure II. Molybdenum-based CO-releasing molecules release ROS and reduce 
NO-induced cGMP accumulation. ROS release by the indicated concentration of 
CO-RMs was measured by chemiluminescence (A and B). RASMC were treated with 
vehicle, CO-RM alone (100μM), DEA/NO alone (1μΜ, Β) or a combination of the 
NO-donor with CO-RM in the presence of IBMX for 15min (C and D). cGMP was 
extracted and measured as described in Methods section. Data are expressed as 
percentage of respective vehicle which was set as 100%;  n=8; *P<0.05 from vehicle 
and #P<0.05 from DEA/NO. 
 
Figure III. Tempol inhibits ALF186-induced ROS production and ALF186-
triggered inhibition of cGMP accumulation. cGMP accumulation was measured in 
RASMCs in the presence of IBMX. Cells were treated with DEA/NO (1μM) or a 
combination of DEA/NO with ALF186 (100μM) in the presence of tempol (30min 
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pretreatment; 1mΜ; A); n=8; *P<0.05 from vehicle and #P<0.05 from DEA/NO. 
ROS release by ALF186 (100μM) was measured by chemiluminescence in the 
absence or presence of tempol (1mM; B); n=4; *P<0.05 from vehicle; #P<0.05 from 
ALF186. 
 
Figure IV. Tempol inhibits ALF436-induced ROS production and ALF436-
triggered inhibition of cGMP accumulation. cGMP accumulation was measured in 
RASMCs in the presence of IBMX. Cells were treated with DEA/NO (1μM) or a 
combination of DEA/NO with ALF436 (100μM) in the presence of tempol (30min 
pretreatment, 1mΜ; A); n=8; *P<0.05 from vehicle and #P<0.05 from DEA/NO. ROS 
release by ALF436 (100μM) was measured by chemiluminescence in the absence or 
presence of tempol (1mM; B); n=4; *P<0.05 from vehicle; #P<0.05 from ALF436. 
 
Figure V: CORM-2 scavenges NO.  NO was mixed with CORM-2 in deoxygenated 
vials and after the indicated time and aliquot was removed. The amount of NO in 
solution was quantified by measuring nitrite formation following air exposure. NO2- 
concentration was determined using the Griess reagent in the absence (A) or presence 
of nitrate reductase (B). The relative concentrations of CORM-2: NO used in the 
experiment were: 1:1; 10:1 or 20:1. The remaining NO is solution (after the reaction 
with CORM-2) upon exposure to air is mainly converted to NO2- since treatment with 
nitrate reductase did not alter the levels of NO2- detected.  
 
Figure VI. Tempol reduces the effect of CO-RMs on cGMP accumuation. cGMP 
accumulation was measured in RASMCs in the presence of IBMX. Cells were treated 
with DEA/NO (1μM), CORM-2 (100μM) or a combination of both in the absence (A) 
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or presence (B) of tempol (30min pretreatment, 1mΜ); n=8; *P<0.05 from vehicle, 
#P<0.05 from DEA/NO; p=0.05 for DEA/NO vs DEA/NO+CORM-2 in the presence 
of tempol. 
 
Figure VII. CORM-2 inhibits SNAP-stimulated relaxation. Rings were pre-treated 
with CORM-2 (200μΜ) or vehicle for 15min and then contracted with phenylephrine; 
they were then exposed to increasing concentrations of the ΝΟ donor SNAP (S-
nitroso-N-acetyl-penicillamine) (A). Pheylephrine-contracted rings were incubated 
with SOD (100IU/ml) or tempol (3mM) for 15min prior to being exposed to CORM-2 
(200μΜ); SNAP was then added at the indicated concentration to elicit 
vasorelaxation. Data are mean ± SEM; n=4-6 *P<0.001 from vehicle, oP<0.001 from 
CORM-2.  
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Table I 
 
102.53
±
12.3
87.75
±
8.14
2--0.00.0CORM-3
298.51*
±
82.82
231.32
±
31.91
2--0.00.0CORM-2
152.42
±
20.29
335.28*
±
108.57
20.01.50.9ALF436
86.60
±
5.86
100.19
±
2.34
20.03.01.7ALF432
84.81
±
11.99
67.56
±
11.98
20.00.01.3ALF411
89.45
±
14.39
93.76
±
10.23
20.11.30.9ALF409
127.78
±
19.04
145.77
±
30.7
202.71.9ALF 186
cGMP
production
% οf vehicle
10μΜ
cGMP
production
% of vehicle
1μΜ
Time/
hours
Equiv.CO
released 
in PBS in 
air
Equiv.CO
released 
in PBS in 
air
Equiv.CO
released in 
RPMI/PBS in 
air
StructureCompound
Mo
CO
OC
NH2
O
OC
N
HN
CH
C
O
Na
Mo
CO CO
O O
OH
CO
O
O
CO2
-
Na3
CO
Ru
O
Cl
OC N
H2
OC C
O
Ru
OC
OC Cl
Cl
CO
Cl
Ru
CO
CO
CO
Cl
Mo
OC
CO
CO
Na5Mo
CO COCO
-O2C CO2
-
N
-O2C
NN CO2
-
-O2C
Mo
CO CO
N
CO
N
N
CO2H
 
Table I. Spontaneous Release of CO and  cGMP production by CO-RMs. 
Molar equivalents of CO released by the indicated CO-RMs in RPMI/FBS or PBS. 
Experiments were performed at room temperature under normoxic and anoxic 
conditions. CO released in the headspace of a closed vial was determined by a gas 
chromatographic method that uses a thermal conductivity detector (GC-TCD). 
Confluent RASMC were treated with vehicle or a CO-releasing molecule (1 and 
10μΜ) in the presence of IBMX for 15min. cGMP was extracted and measured as 
described. Data are expressed as percentage of respective vehicle which was set as 
100%; n=8-12; *P<0.05 from vehicle. 
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